Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Abstract

BACKGROUND The programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. We tested the anti–PD-1 antibody lambrolizumab (previously known as MK-3475) in patients with advanced melanoma. METHODS We administered lambrolizumab intravenously at a dose of 10 mg per kilogram of body weight every 2 or 3 weeks or 2 mg per kilogram every 3 weeks in patients with advanced melanoma, both those who had received prior treatment with the immune checkpoint inhibitor ipilimumab and those who had not. Tumor responses were assessed every 12 weeks. RESULTS A total of 135 patients with advanced melanoma were treated. Common adverse events attributed to treatment were fatigue, rash, pruritus, and diarrhea; most of the adverse events were low grade. The confirmed response rate across all dose cohorts, evaluated by central radiologic review according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, was 38% (95% confidence interval [CI], 25 to 44), with the highest confirmed response rate observed in the cohort that received 10 mg per kilogram every 2 weeks (52%; 95% CI, 38 to 66). The response rate did not differ significantly between patients who had received prior ipilimumab treatment and those who had not (confirmed response rate, 38% [95% CI, 23 to 55] and 37% [95% CI, 26 to 49], respectively). Responses were durable in the majority of patients (median follow-up, 11 months among patients who had a response); 81% of the patients who had a response (42 of 52) were still receiving treatment at the time of analysis in March 2013. The overall median progression-free survival among the 135 patients was longer than 7 months. CONCLUSIONS In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects. (Funded by Merck Sharp and Dohme; ClinicalTrials.gov number, NCT01295827.)

Profiles of brain metastases: Prioritization of therapeutic targets

“…The interaction between the immune system, tumor and the tumor microenvironment has been the focus of intense investigation—specifically the role of the PD‐1/PDL‐1 signaling axis,38 The efficacy of PD‐1 inhibition (i.e., nivolumab and pembrolizumab) as a monotherapy or in combination therapy has shown favorable survival in clinical trials for patients with advanced melanoma and NSCLC 39, 40, 41, 42, 43. However, the role of immune checkpoint inhibitors in the treatment of CNS cancers, including metastasis, is currently being defined,44, 45 and our current results provide further support for these agents in this context.…”

The comprehensive molecular landscape of the immunologic co-stimulator B7 and TNFR ligand receptor families in colorectal cancer: immunotherapeutic implications with microsatellite instability

“…Although anti-PD-1/PD-L1 antibodies have been demonstrated to induce significant durable tumor regressions in patients with renal cancer, melanoma and non-small cell lung cancer, 24,28,29 CRC cases exhibit very low response rates, except those with MSI-H status. 6,7 MSI is a consequence of impaired DNA mismatch repair, resulting in mutation accumulations to create a rich source of tumor-specific neoantigens.…”

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

“…PD-1 immune checkpoint blockade therapy induces a high rate of anti-melanoma response and provides unprecedented clinical benefits (Hamid et al, 2013;Topalian et al, 2012). This therapeutic approach has also been shown to be active against a growing list of human malignancies, and clinical testing of combinations of PD-1 (or PD-L1) with other treatment targets has already begun (Sharma and Allison, 2015).…”